Loading the section…
The price of Sarepta Therapeutics, Inc. (SRPT) on October 9, 2026 is 17.85 USD, −1.98% on the day. Over 52 weeks the stock traded between 14.68 USD and 24.68 USD; the price now sits 32% of the way up that range. Over the past year the price changed by −23.65%. The P/E ratio is 52.5, which is above the sector median (25.0). Market capitalization is 3.42 billion USD, rank 51 among 373 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 2 November 2026 · Earnings calendar
Change over the period shown (line colour): −18.72 %
Sarepta Therapeutics, Inc. trades on Nasdaq under the ticker SRPT. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks SRPT has traded between 14.68 $ and 24.68 $. As of 9 October 2026 the price stood 31.70 % of the way from the 52-week low to the high.
Over one year SRPT shares fell 23.65 %; over six months they fell 15.72 %. Volatility over 90 days is 59.28 %. Dividends are not included: this is price change only, as of 9 October 2026.
SRPT trades at a price-to-earnings ratio of 52.5, above the sector median of 25.0. Price to sales is 1.6, below the sector median of 4.0. Price to book is 2.3, below the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 18.25 | 18.53 | 17.68 | 17.85 | 3M |
| 8 October 2026 | 17.28 | 18.28 | 17.20 | 18.21 | 4M |
| 7 October 2026 | 17.28 | 17.67 | 16.98 | 17.50 | 3M |
| 6 October 2026 | 17.60 | 17.65 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Sarepta Therapeutics, Inc. (SRPT) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 2.2bn $, net income was 65.1m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:215 FIRST STREET SUITE 415, CAMBRIDGE, MA, 02142, US
Sarepta Therapeutics, Inc. reported revenue of 2.2B $ and net income of 65M $ over the last four quarters. Net margin is 2.98 %. Revenue changed by −2.20 % year over year. Earnings per share are 0.34 $. Market capitalisation is 3.4B $.
SRPT has a return on equity of 4.32 %, above the sector median of −41.68 %. Return on assets is 2.05 %, above the sector median of −32.11 %. Operating margin is −1.88 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 17.04 |
| 17.31 |
| 3M |
| 5 October 2026 | 17.39 | 17.55 | 17.10 | 17.49 | 2M |
| 2 October 2026 | 17.75 | 17.76 | 17.21 | 17.50 | 3M |
| 1 October 2026 | 18.14 | 18.25 | 17.52 | 17.57 | 3M |
| 30 September 2026 | 18.64 | 18.69 | 18.06 | 18.22 | 2M |
| 29 September 2026 | 18.68 | 18.74 | 18.38 | 18.64 | 1M |
| 28 September 2026 | 18.43 | 18.86 | 17.64 | 18.80 | 2M |
| 25 September 2026 | 18.49 | 18.77 | 18.02 | 18.67 | 2M |
| 24 September 2026 | 18.85 | 19.14 | 18.05 | 18.39 | 3M |
| 23 September 2026 | 20.72 | 20.76 | 18.74 | 18.95 | 4M |
| 22 September 2026 | 20.46 | 21.19 | 20.19 | 20.81 | 2M |
| 21 September 2026 | 20.29 | 20.50 | 19.97 | 20.14 | 2M |
| 18 September 2026 | 20.63 | 20.74 | 19.62 | 20.11 | 6M |
| 17 September 2026 | 20.23 | 21.75 | 19.97 | 20.67 | 3M |
| 16 September 2026 | 20.68 | 20.89 | 19.72 | 19.76 | 3M |
| 15 September 2026 | 20.81 | 21.06 | 20.29 | 20.72 | 3M |
| 14 September 2026 | 20.55 | 21.40 | 20.38 | 20.92 | 2M |